A novel, eye-tracking metrics device aided in the detection of dementia risk in a small population of Colombian individuals with differing levels of education, according to a poster presented at CTAD.
“A key factor precluding the validity and generalizability of novel developments in the field of early diagnosis is their cultural bias,” Mario A. Parra, MD, PhD, neuroscientific officer at ViewMind, and colleagues wrote.
Parra and colleagues tested the efficacy of the ViewMind AI Solution, a novel vision-based device that utilizes neurocognitive biomarkers, artificial intelligence and